Literature DB >> 15320847

Allograft-induced proliferation of vascular smooth muscle cells: potential targets for treating transplant vasculopathy.

Michael V Autieri1.   

Abstract

Despite advances in immunosuppressive drugs, coronary artery transplant vasculopathy (CATV) is the major cause of graft failure that limits long-term survival of cardiac transplantation. The pathogenesis of CATV involves a chronic immune response of the recipient to the donor vasculature in which activated recipient immune cells damage the endothelium and produce cytokines, resulting in vascular smooth muscle cell (VSMC) activation. Activated VSMC migrate from the media into the lumen, proliferate, and elaborate cytokines and matrix proteins, resulting in loss of lumen diameter and vascular contractility. Because of its extensive nature, interventions which are successful in patients with conventional coronary artery disease are often not applicable to the majority of patients with CATV. Although intended for immune suppression, many immunosuppressive agents owe at least part of their efficacy to their anti proliferative effects on VSMC, including rapamycin, mycophenolic acid, cyclosporin, calcium channel blockers, and HMG CoA reductase inhibitors. Because activation of VSMC is responsible for most of the obliterative arterial intimal thickening present in solid organ allografts, the induction of expression of a selected set of genes may reflect the status of acceptance of the vasculature by the recipient, and the activation, migration, and proliferation of VSMC represent potential points for therapeutic intervention. The risk of infection and malignancy associated with immunosuppressive therapy further promote the need to identify a molecular target which directly modulates the VSMC response to injury. This review will summarize the anti proliferative effects that immunosuppressive drugs have on VSMC proliferation. We will also describe efforts to define the genes which regulate the vascular response to allograft injury, and describe how some of these proteins may represent targets to reduce VSMC proliferation and attenuate CATV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15320847     DOI: 10.2174/1570161033386772

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  9 in total

1.  Adenovirus-mediated overexpression of glutathione-s-transferase mitigates transplant arteriosclerosis in rabbit carotid allografts.

Authors:  Ya Xu; Bin Gong; Yongzhen Yang; Yogesh C Awasthi; Paul J Boor
Journal:  Transplantation       Date:  2010-02-27       Impact factor: 4.939

Review 2.  Activation transcription factor-4 and the acute vascular response to injury.

Authors:  Kristine P Malabanan; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

3.  A reproducible mouse model of chronic allograft nephropathy with vasculopathy.

Authors:  Abolfazl Zarjou; Lingling Guo; Paul W Sanders; Roslyn B Mannon; Anupam Agarwal; James F George
Journal:  Kidney Int       Date:  2012-08-08       Impact factor: 10.612

Review 4.  Vascular Signaling in Allogenic Solid Organ Transplantation - The Role of Endothelial Cells.

Authors:  Laura Kummer; Marcin Zaradzki; Vijith Vijayan; Rawa Arif; Markus A Weigand; Stephan Immenschuh; Andreas H Wagner; Jan Larmann
Journal:  Front Physiol       Date:  2020-05-08       Impact factor: 4.566

5.  AAV-Mediated Expression of AP-1-Neutralizing RNA Decoy Oligonucleotides Attenuates Transplant Vasculopathy in Mouse Aortic Allografts.

Authors:  Anca Remes; Maximilian Franz; Franziska Mohr; Antje Weber; Kleopatra Rapti; Andreas Jungmann; Matthias Karck; Markus Hecker; Klaus Kallenbach; Oliver J Müller; Rawa Arif; Andreas H Wagner
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-02       Impact factor: 6.698

Review 6.  Cardiovascular effects of immunosuppression agents.

Authors:  Aly Elezaby; Ryan Dexheimer; Karim Sallam
Journal:  Front Cardiovasc Med       Date:  2022-09-21

7.  A20 Haploinsufficiency Aggravates Transplant Arteriosclerosis in Mouse Vascular Allografts: Implications for Clinical Transplantation.

Authors:  Herwig P Moll; Andy Lee; Clayton R Peterson; Jesus Revuelta Cervantes; Brandon M Wojcik; Anshul Parulkar; Alessandra Mele; Philip J LoGerfo; Jeffrey J Siracuse; Eva Csizmadia; Cleide G da Silva; Christiane Ferran
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

8.  MicroRNA-30 inhibits neointimal hyperplasia by targeting Ca(2+)/calmodulin-dependent protein kinase IIδ (CaMKIIδ).

Authors:  Yong Feng Liu; Amy Spinelli; Li-Yan Sun; Miao Jiang; Diane V Singer; Roman Ginnan; Fatima Z Saddouk; Dee Van Riper; Harold A Singer
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

9.  HHEX: A Crosstalker between HCMV Infection and Proliferation of VSMCs.

Authors:  Lingfang Li; Meitong Liu; Leitao Kang; Yifan Li; Ziyu Dai; Bing Wang; Shuiping Liu; Liyu Chen; Yurong Tan; Guojun Wu
Journal:  Front Cell Infect Microbiol       Date:  2016-11-30       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.